Jyong Biotech (NASDAQ:MENS) Trading Up 9.1% - What's Next?

Key Points

• Jyong Biotech's stock price increased by 9.1% to $59.00, following a previous close of $54.10, despite a significant drop in trading volume.
• The company's 50-day simple moving average stands at $30.26, indicating potential for future growth.
• Wall Street Zen recently upgraded Jyong Biotech to a "hold" rating, suggesting a more favorable outlook from analysts.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) rose 9.1% during mid-day trading on Wednesday . The stock traded as high as $59.03 and last traded at $59.00. Approximately 27,876 shares traded hands during trading, a decline of 85% from the average daily volume of 184,802 shares. The stock had previously closed at $54.10.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.

Jyong Biotech Stock Down 15.7%

The stock has a 50-day moving average price of $33.37.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.